Back
Monday, 27 Apr, 2020
Global regulatory agility during covid-19 and other health emergencies
Enhanced collaboration among authorities is key to ensuring timely access to high-quality health products worldwide. Read more in this commentary for BMJ, featuring Prof John Lim and co-authored with leading regulatory experts from the Vaccine and Infectious Disease Organization, World Health Organization (WHO), Bill & Melinda Gates Foundation and other agencies.
Tippi K Mak
consultant 1 2 3, John CW Lim
executive director and policy core lead 1 2, Prapassorn Thanaphollert
consultant 4 , Gugu N Mahlangu
director general 5, Emer Cooke
director of regulation and prequalification 6, Murray M Lumpkin
deputy director of integrated development and lead for global regulatory systems initiatives 7 1Centre of Regulatory Excellence, Duke-NUS Medical School, Singapore; 2SingHealth Duke-NUS Global Health Institute, Singapore; 3Vaccine and Infectious Disease Organization-International Vaccine Centre, University of Saskatchewan, Canada; 4Food and Drug Administration Thailand, Bangkok, Thailand; 5Medicines Control Authority of Zimbabwe, Harare, Zimbabwe; 6Access to Medicines and Health Products Division, World Health Organization, Geneva, Switzerland; 7Bill & Melinda Gates Foundation, Seattle, USA Click
here to read the article.
CoRE CN: 2020_A003_CoRE_Global regulatory agility during covid-19 and other health emergencies